Ambit Biosciences raises $30 million through Series D-2 equity financing Ambit Biosciences.

‘We have become pleased our existing traders have reaffirmed their confidence in the Company, providing us with sufficient funding to go after our strategy and enabling us to withdraw our programs for an initial public offering.’ ‘We have become committed inside our support of Ambit’s research and development efforts. The Company has made good improvement in furthering the medical development of all of its clinical resources including its lead substance. Its current pipeline and method of optimizing and selecting potential new medicines provides Ambit with a competitive edge that we believe can be unmatched in the market,’ stated Allan Marchington, Partner, Apposite Capital.. Ambit Biosciences raises $30 million through Series D-2 equity financing Ambit Biosciences , an emerging biopharmaceutical business engaged in the advancement of kinase inhibitors for the treatment of cancer and other circumstances, today announced that it has completed a Series D-2 round of collateral financing, raising $30 million in new capital.The study is designed to demonstrate the protection of PRT4445 and its own ability to reverse the anticoagulation activity of ELIQUIS and various other Element Xa inhibitors, including betrixaban, Portola's Stage 3 oral Aspect Xa inhibitor. Bristol-Myers Squibb and Pfizer can make an undisclosed money payment to Portola upon initiation of the proof-of-concept research with ELIQUIS and will provide advancement and regulatory guidance for the study. Portola retains 100 % global advancement and commercialization rights for PRT4445.

Other entries from category "drugs":

Random entries